Spasticity, Dystonia, and Other Movement Disorders: A Comprehensive Treatment Guide

  • A. Sebastian Schroeder
  • Steffen Berweck
  • Edward R. Dabrowski
  • Florian Heinen


Spasticity and movement disorders are rarely in focus of acute management in pediatric neurology. However, certain conditions do require more acute medical interventions, including acute dystonic reactions, intensified preexisting spasticity and/or dystonia, and rapid development of spasticity in the post-acute phase following focal (e.g. stroke) or global (e.g. anoxia) CNS pathology. In the present chapter we present typical symtoms, underlying pathophysiology, recommended assessments, and recommended interventions for spasticity and movements disorders, with an emphasis on acute management.


Deep Brain Stimulation Botulinum Toxin Hereditary Spastic Paraplegia Gross Motor Function Classification System Intrathecal Baclofen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980;30(12):1303–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Dietz V. Cerebral palsy and muscle transformation. Dev Med Child Neurol. 1995;37:180–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111(1):e89–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Lieber RL, Steinman S, Barash IA, Chambers H. Structural and functional changes in spastic skeletal muscle. Muscle Nerve. 2004;29(5):615–27.PubMedCrossRefGoogle Scholar
  5. 5.
    Scholtes VA, Becher JG, Beelen A, Lankhorst GJ. Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. Dev Med Child Neurol. 2006;48(1):64–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6(4):23–35.CrossRefGoogle Scholar
  7. 7.
    McDowell BC, Hewitt V, Nurse A, Weston T, Baker R. The variability of goniometric measurements in ambulatory children with spastic cerebral palsy. Gait Posture. 2000;12(2):114–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Allington NJ, Leroy N, Doneux C. Ankle joint range of motion measurements in spastic cerebral palsy children: intraobserver and interobserver reliability and reproducibility of goniometry and visual estimation. J Pediatr Orthop B. 2002;11(3):236–9.PubMedGoogle Scholar
  9. 9.
    Mackey AH, Lobb GL, Walt SE, Stott NS. Reliability and validity of the Observational Gait Scale in children with spastic diplegia. Dev Med Child Neurol. 2003;45(1):4–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Maathuis KG, van der Schans CP, van Iperen A, Rietman HS, Geertzen JH. Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing scale. J Pediatr Orthop. 2005;25(3):268–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Russell DJ, Leung KM, Rosenbaum PL. Accessibility and perceived clinical utility of the GMFM-66: evaluating therapists’ judgements of a computer-based scoring program. Phys Occup Ther Pediatr. 2003;23(2):45–58.PubMedGoogle Scholar
  12. 12.
    Eliasson AC, Krumlinde-Sundholm L, Rosblad B, Beckung E, Arner M, Ohrvall AM, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006;48(7):549–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Carswell A, McColl MA, Baptiste S, Law M, Polatajko H, Pollock N. The Canadian occupational performance measure: a research and clinical literature review. Can J Occup Ther. 2004;71(4):210–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Cusick A, McIntyre S, Novak I, Lannin N, Lowe K. A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. Pediatr Rehabil. 2006;9(2):149–57.PubMedGoogle Scholar
  15. 15.
    Ward AB, Wissel J, Molteni F, Yakovleff A, Gedin S, Aguilar M, et al. European consensus statement on the use of botulinum toxin type A in the management of adult spasticity. Acta Neurol Belg. 2003;103(1):39.PubMedGoogle Scholar
  16. 16.
    Gormley Jr ME, O’Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve. 1997;6:S14–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Sun SF, Hsu CW, Hwang CW, Hsu PT, Wang JL, Yang CL. Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke. Phys Ther. 2006;86(10):1387–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002;288(11):1357–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1):45–66.PubMedCrossRefGoogle Scholar
  20. 20.
    Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17(2):9–37.PubMedCrossRefGoogle Scholar
  22. 22.
    Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol. 2010;17(2):38–56.PubMedCrossRefGoogle Scholar
  23. 23.
    de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96(6):3200–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Schroeder AS, Ertl-Wagner B, Britsch S, Schroder JM, Nikolin S, Weis J, et al. Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers. Mov Disord. 2009;24(10):1494–503.PubMedCrossRefGoogle Scholar
  25. 25.
    Schroeder AS, Koerte I, Berweck S, Ertl-Wagner B, Heinen F. How doctors think—and treat with botulinum toxin. Dev Med Child Neurol. 2010;52:875–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Chin TS, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A: a comparison between manual needle placement and placement guided by electrical stimulation. Dev Med Child Neurol. 2003;45 Suppl 96:286–91.Google Scholar
  27. 27.
    Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy—a short review of different injection techniques. Neurotox Res. 2006;9(2–3):189–96.PubMedCrossRefGoogle Scholar
  28. 28.
    Barry MJ, Van Swearingen JM, Albright AL. Reliability and responsiveness of the Barry-Albright Dystonia Scale. Dev Med Child Neurol. 1999;41(6):404–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985;35(1):73–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003;18(3):303–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Haranhalli N, Anand D, Wisoff JH, Harter DH, Weiner HL, Blate M, et al. Intrathecal baclofen therapy: complication avoidance and management. Childs Nerv Syst. 2011;27(3):421–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Zuckerbraun NS, Ferson SS, Albright AL, Vogeley E. Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care. 2004;20(11):759–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Muller-Schwefe G, Penn RD. Physostigmine in the treatment of intrathecal baclofen overdose. Report of three cases. J Neurosurg. 1989;71(2):273–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • A. Sebastian Schroeder
    • 1
  • Steffen Berweck
    • 2
  • Edward R. Dabrowski
    • 3
    • 4
  • Florian Heinen
    • 1
  1. 1.Department of Pediatric Neurology and Developmental Medicine, Social Pediatrics, Hauner Children’s HospitalUniversity of MunichMunichGermany
  2. 2.Departments of Neuropaediatrics and Neurological RehabilitationEpilepsy Centre for Children and Adolescents, Day Clinic for Neuropaediatrics, Schoen Klinik VogtareuthVogtareuthGermany
  3. 3.Pediatric Physical Medicine and Rehabilitation, Children’s Hospital of MichiganWayne State UniversityDetroitUSA
  4. 4.Department of Pediatrics, Children’s Hospital of MichiganWayne State UniversityDetroitUSA

Personalised recommendations